TRANSPOSAGEN BIOPHARMACEUTICALS, INC.

Basic Information

201 West Second St.
Lexington, KY, 40507-1112

http://www.transposagenbio.com

Company Profile

n/a

Additional Details

Field Value
DUNS: 145182338
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 15


  1. Novel reporter cell lines for neurotoxicant assays

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): While it has been demonstrated that gene mutations are associated with an increasing number of neurodegenerative syndromes, environmental neurotoxicants remain a k ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Novel method to create knockout rats using endonucleases and spermatogonial stem

    Amount: $2,016,115.00

    DESCRIPTION (provided by applicant): The laboratory rat is a preferred rodent model in pre-clinical drug studies. Their larger size facilitates procedures otherwise difficult in mice, includng studies ...

    SBIR Phase II 2014 Department of Health and Human Services
  3. Novel method to create knockout rats using endonucleases and spermatagonialstem

    Amount: $342,046.00

    DESCRIPTION (provided by applicant): The laboratory rat is the preferred rodent model in pre-clinical drug studies and encompasses the bulk of accumulated knowledge in drug development. Their larger s ...

    SBIR Phase I 2011 Department of Health and Human Services
  4. Generation of Site-Specific Recombinase-Expressing Transgenic Rats using an Enhan

    Amount: $240,637.00

    DESCRIPTION (provided by applicant): The goal is to create site-specific recombinase (SSR)-expressing transgenic rats in an efficient and unbiased manner through a transposon-mediated in vivo gene ...

    SBIR Phase I 2010 Department of Health and Human Services
  5. Creation of hyperactive transposons for mutagenesis in rodents

    Amount: $1,647,590.00

    DESCRIPTION (provided by applicant): The rat is a favored model for many types of human disease for which mice are not suitable. As opposed to the mouse, rats and humans also share more similarity in ...

    SBIR Phase II 2010 Department of Health and Human Services
  6. Tissue-Specific Mutagenesis in Rat as an In Vivo Tool for Colon Cancer Gene Disco

    Amount: $312,628.00

    DESCRIPTION (provided by applicant): The outcome of this SBIR application will be a rat model of colorectal cancer (CRC), which can be used to discover new targets for colon cancer therapy. CRC rats w ...

    SBIR Phase I 2009 Department of Health and Human Services
  7. Creation of hyperactive transposons for mutagenesis in rodents

    Amount: $295,614.00

    DESCRIPTION (provided by applicant): This project aims to rapidly produce rat mutants through a transposon-based method of mutagenesis. The rat is a favored model for many types of human disease for w ...

    SBIR Phase I 2009 Department of Health and Human Services
  8. L1 retrotransposon-based mutagenesis for rat models of human diseases

    Amount: $650,666.00

    DESCRIPTION (provided by applicant): In many aspects the rat is a better animal model than the mouse for functional genomic studies. The physiology and drug metabolism of rats and humans are more simi ...

    SBIR Phase II 2007 Department of Health and Human Services
  9. L1 mutagenesis for mammalian models of human diseases

    Amount: $99,724.00

    DESCRIPTION (provided by applicant): Transposagen is developing an innovative mammalian random mutagenesis system that uses an L1 retrotransposon for direct germ-line mutagenesis. Transposagen's goal ...

    SBIR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government